Posts

Hengrui, Kailera’s GLP‑1 Pill Posts Encouraging Efficacy but High Side Effect Rates in Late‑Stage China Trials

on
Hengrui and Kailera’s oral GLP-1 pill, HRS-7535 (KAI-7535), has met its main endpoints in two late‑stage China trials for obesity and type 2 diabetes, supporting a planned regulatory submission in China but raising concerns about tolerability. In the obesity trial HARBOR‑1, patients receiving 120 mg and 180 mg of HRS‑7535 lost 8% and 9.8% of their body weight at week 44 versus 2.4% on placebo. In the diabetes trial OUTSTAND‑1/‑2, the highest HRS‑7535 dose (90 mg) reduced HbA1c by 1.68%, compared with 1.28% for dapagliflozin (Farxiga), demonstrating non‑inferior glycemic control. About 70% of patients on HRS‑7535 experienced nausea and up to 68.6% reported vomiting, both far higher than placebo rates (16.2% and 4.5%, respectively), though most adverse events were mild to moderate and no liver safety signal was seen. Analysts note that the high gastrointestinal side‑effect rates may complicate the ongoing U.S. development program for this oral GLP‑1 candidate. Sources: Hengru...

Vera’s IgAN Approval Kicks Off Competition with Otsuka

on

Biopharma bites: Job cuts at Novartis, fresh funding for MeiraGTx and Fore, plus Boehringer's latest deal – 2026 update

on

Altasciences and Evidence Matters Advance AI‑Driven Drug Development With Nonclinical Automation Breakthrough – Recent Highlights

on

Endevica spinout Kalohexis files confidential IPO to advance obesity drug rivaling GLP-1s

on

MeiraGTx scoops up to $400M from Oberland Capital to push gene therapies toward commercialization

on

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial

on

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

on

Vertex’s $10B deal for Crinetics marks its biggest acquisition to date

on

Compass Pathways Hypes Durability of Psilocybin for Depression Ahead of Year‑End FDA Filing

on

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

on

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting (July 2026)

on

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

on